David Bushnell, MS, is affiliated with Cytel, Inc in Waltham, Massachusetts. His publications focus on the treatment of major depressive disorder (MDD), specifically investigating the safety and efficacy of esmethadone in patients with MDD, including those with inadequate responses to standard antidepressants. His work includes long-term open-label studies and phase 3 randomized controlled trials. Bushnell has frequently collaborated with Andrea Mattarei, Andrew J. Cutler, Charles E. Inturrisi, Charles W. Gorodetzky, and Clotilde Guidetti.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
